Healthcare Sales & Marketing Network News: T cells

Searching News Database: T cells

HSMN NewsFeed - 13 Jul 2026
Aethlon Medical Continues to Observe Directional Changes in Second Cohort of Australian Oncology Clinical Trial Evaluating Hemopurifier(R)
Devices Oncology

HSMN NewsFeed - 14 May 2026
CREATE Medicines Announces $122 Million Series B Financing to Advance In Vivo CAR Pipeline in Autoimmune Disease and Oncology
Biopharmaceuticals Oncology Venture Capital

HSMN NewsFeed - 29 Dec 2025
FDA Accepts for Review INOVIO's BLA for INO-3107 for the Treatment of Adults with Recurrent Respiratory Papillomatosis (RRP)
Biopharmaceuticals FDA

HSMN NewsFeed - 15 Aug 2025
Precigen Announces Full FDA Approval of PAPZIMEOS (zopapogene imadenovec-drba), the First and Only Approved Therapy for the Treatment of Adults with Recurrent Respiratory Papillomatosis
Biopharmaceuticals FDA

HSMN NewsFeed - 20 Jun 2025
Lomond Therapeutics Announces U.S. FDA Clearance of IND Application for Lonitoclax, a Selective BCL2 Inhibitor with Limited Immune Suppression and Improved Safety Compared to Venetoclax and Venetoclax- Like Molecules
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 13 Jun 2025
U.S. Food & Drug Administration (FDA) Approves Investigational New Drug (IND) Application for Myrio's Lead Product (PHOX2B PC-CAR T) for the Treatment of Neuroblastoma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 10 Feb 2025
Nektar Therapeutics Receives Fast Track Designation for Rezpegaldesleukin for the Treatment of Moderate-to-Severe Atopic Dermatitis
Biopharmaceuticals Dermatology FDA

HSMN NewsFeed - 9 Jan 2025
RheumaGen, Inc. Launches with $15 Million Series A Financing to Advance a New Class of HLA Gene-Editing Therapies for Major Autoimmune Diseases
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 22 Oct 2024
AvenCell Raises $112 Million in Series B; Funding Led by Novo Holdings
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 28 Jun 2024
AbbVie Receives Positive CHMP Opinion for Epcoritamab (TEPKINLY(R)) for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 18 Apr 2024
Pathios Therapeutics Raises $25M in First Close of Series B Financing to Advance First-in-Class Immunotherapy Approach into Clinic
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 19 Jan 2024
Kyverna Therapeutics Granted FDA Fast Track Designation for KYV-101 in the Treatment of Patients With Refractory Progressive Multiple Sclerosis
Regenerative Medicine Neurology FDA

HSMN NewsFeed - 13 Dec 2023
Kyverna Therapeutics Granted FDA Fast Track Designation for KYV-101 in the Treatment of Patients With Refractory Myasthenia Gravis
Biopharmaceuticals FDA

HSMN NewsFeed - 3 Aug 2023
Kyverna Therapeutics Extends Series B Financing Round to $145 Million and Brings in New Investors
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 6 Jun 2023
Acepodia Secures $100 Million Series D Financing to Advance
Biopharmaceuticals Oncology Venture Capital

HSMN NewsFeed - 28 Feb 2023
Verismo Therapeutics Announces $7 Million Pre-Series A with BRV Capital Management as Lead Investor
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 9 Dec 2022
Janssen Submits Biologics License Application to U.S. FDA for Talquetamab for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 21 Sep 2022
Immunitas Therapeutics Receives FDA Clearance of IND Application for IMT-009 in Solid Tumors and Hematological Malignancies
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 16 Sep 2022
Marengo Therapeutics Advances First-In-Class Selective T cell Activator, STAR0602, into Human Trials in Solid Tumors and Enters Cooperative Research and Development Agreement with the National Cancer Institute
Biopharmaceuticals Oncology

HSMN NewsFeed - 10 Aug 2022
GentiBio Announces Collaboration with Bristol Myers Squibb to Pioneer Engineered Treg Therapies for Inflammatory Bowel Diseases
Biopharmaceuticals Gastroenterology

HSMN NewsFeed - 29 Jun 2022
Artax Biopharma Appoints D. Scott Batty, Jr., M.D. as Chief Medical Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 9 May 2022
Marengo Therapeutics Appoints Ke Liu, MD, PhD, and Bruce Chabner, MD, to Key Leadership Roles, Strengthening Marengo's Development Team and Supporting Translation to the Clinic
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 19 Apr 2022
Regeneron to Acquire Checkmate Pharmaceuticals and Its Investigational Immune Activator for Potential Use in Multiple Tumor Types
Biopharmaceuticals Oncology Mergers & Acquisitions

HSMN NewsFeed - 17 Mar 2022
TC BioPharm Announces FDA Orphan Drug Status Granted for OmnImmune(R)
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 22 Feb 2022
TC Biopharm Announces Appointment of New Board Members
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 10 Feb 2022
GentiBio Appoints Industry Veteran Chuck Silberstein as Chief Financial Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 26 Jan 2022
Kyverna Therapeutics Closes $85 Million Series B Financing led by Northpond Ventures
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 25 Nov 2021
Priothera Appoints Elisabeth Kueenburg M.D., as Chief Medical Officer
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 8 Nov 2021
Marengo Therapeutics Launches with $80M from ATP, Appoints CEO Zhen Su, MD, to Deliver Breakthrough Cancer Treatments Using Its Selective T Cell Activation Repertoire (STAR) Platform
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 7 Oct 2021
AffyImmune Therapeutics Announces $30M Series A+ Financing from ORI Capital
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 6 Oct 2021
U.S. FDA Accepts COUR Pharmaceuticals Investigational New Drug Application (IND) for a Proof-of-Concept Study for the Treatment of Primary Biliary Cholangitis (PBC)
Biopharmaceuticals FDA

HSMN NewsFeed - 16 Sep 2021
LUMAKRAS(TM) (Sotorasib) Combined With Vectibix(R) (Panitumumab) Showed Encouraging Efficacy And Safety In Patients With KRAS G12C-Mutated Colorectal Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 30 Aug 2021
Poseida Therapeutics Announces FDA Clearance of Investigational New Drug Application for P-BCMA-ALLO1, an Allogeneic CAR-T Candidate for Relapsed/Refractory Multiple Myeloma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 23 Aug 2021
Elixiron Immunotherapeutics Announces Closing of $27 Million Series A-1 Financing Round to Progress Alzheimer's Disease and Vitiligo Clinical-Stage Assets
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 11 Aug 2021
GentiBio Announces $157M Series A Financing to Advance Engineered Regulatory T cells as Transformative Therapeutics with Potential to Restore Immune Tolerance and Durably Treat Autoinflammation
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 6 Aug 2021
BioInvent Announces Second Clinical Trial Collaboration and Supply Agreement to Evaluate BI-1808 in Combination with KEYTRUDA(R) (pembrolizumab) in Patients with Advanced Solid Tumors
Biopharmaceuticals Oncology

HSMN NewsFeed - 23 Jul 2021
ImaginAb Announces Extension Of Long-Standing Partnership With Boehringer Ingelheim
Biopharmaceuticals Radiology Licensing

HSMN NewsFeed - 2 Jun 2021
MorphImmune, Inc. Appoints Ronald Martell as President and CEO
Biopharmaceuticals Personnel

HSMN NewsFeed - 1 Jun 2021
Kineta Closes $10 Million Financing Round to Advance Anti-VISTA Immuno-oncology Program
Biopharmaceuticals Oncology Venture Capital Personnel

HSMN NewsFeed - 1 Jun 2021
Amgen and Kyowa Kirin to Jointly Develop and Commercialize KHK4083, a Phase 3-Ready, Potential First-In-Class Treatment for Atopic Dermatitis
Biopharmaceuticals Dermatology

HSMN NewsFeed - 18 May 2021
Interius BioTherapeutics Raises $76M Series A Financing to Advance Breakthrough Cell and Gene Therapy Platform
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 17 May 2021
AffyImmune Therapeutics' AIC100 Granted Fast Track Designation for Treating Thyroid Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 11 May 2021
Appia Bio Launches With $52 Million Series A Financing and Establishes Scientific Advisory Board
Biopharmaceuticals Venture Capital Personnel

HSMN NewsFeed - 23 Mar 2021
Poseida Therapeutics Announces Carl June, M.D., to Chair Immuno-Oncology Scientific Advisory Board
Biopharmaceuticals Personnel

HSMN NewsFeed - 5 Mar 2021
PACT Pharma Announces Planned Retirement of CEO Alex Franzusoff; Veteran Biotech Executive Scott Garland Named as Successor
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 23 Feb 2021
Elicio Therapeutics Announces FDA Clearance of IND application for ELI-002-- A Therapeutic Vaccine Targeting mutated KRAS Cancers
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 6 Jan 2021
Myeloid Therapeutics Launches with Over $50 Million in Financing and Two Clinical Trials
Biopharmaceuticals Oncology Venture Capital

HSMN NewsFeed - 18 Nov 2020
Umoja Biopharma Launches with $53M Series A Financing to Develop Fully Integrated, Scalable, In Vivo Immunotherapy Platform
Biopharmaceuticals Oncology Venture Capital

HSMN NewsFeed - 17 Nov 2020
Celularity Announces Appointments of Chief Medical Officer and Senior Vice President of Regulatory Affairs
Biopharmaceuticals Personnel

HSMN NewsFeed - 10 Nov 2020
Cytocom, Inc. Appoints Taunia Markvicka, PharmD., MBA, Chief Operating Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 9 Nov 2020
DTx Pharma Announces Appointment of Denise Bevers as Chief Operating Officer
Biopharmaceutical Drug Delivery Personnel

HSMN NewsFeed - 9 Oct 2020
Innovent and Lilly Jointly Announce the NMPA Granted Marketing Approval for HALPRYZA(R) (Rituximab Injection) in China
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 17 Sep 2020
Novo Ventures co-leads US $83m series C financing in Lava Therapeutics
Biopharmaceuticals Oncology Venture Capital

HSMN NewsFeed - 24 Aug 2020
Connect Biopharma Completes $115 Million Series C Financing to Advance Ongoing Clinical Trials in Atopic Dermatitis and Ulcerative Colitis and Initiate Additional Clinical Programs
Biopharmaceuticals Venture Capital Personnel

HSMN NewsFeed - 25 Jun 2020
Enterome Completes €46.3 Million ($52.6 Million) Financing to Progress the Clinical Development of Its Therapeutic Pipeline
Biopharmaceuticals Oncology Venture Capital

HSMN NewsFeed - 27 Apr 2020
CARsgen Therapeutics Receives Positive EMA Opinion on Orphan Drug Designation for Fully Human Anti-BCMA CAR-T Cells (CT053) for the Treatment of Multiple Myeloma
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 22 Apr 2020
Novartis Kymriah(R) receives FDA Regenerative Medicine Advanced Therapy designation in follicular lymphoma
Biopharmaceuticals Regenerative Medicine Oncology FDA

HSMN NewsFeed - 16 Apr 2020
Digital Therapeutics Leader Biofourmis Expands into Oncology Market with Strategic Acquisition of Gaido Health
Biopharmaceuticals Oncology Acquisitions

HSMN NewsFeed - 24 Mar 2020
Apexigen Completes $123 Million Series C Financing To Advance Clinical Pipeline
Biopharmaceuticals Oncology Venture Capital

HSMN NewsFeed - 7 Feb 2020
Elios Therapeutics Presents New Phase IIb Data for Personalized Cancer Vaccine in High-Risk Melanoma Patients at the 2020 ASCO-SITC Clinical Immuno-Oncology Symposium
Biopharmaceuticals Oncology

HSMN NewsFeed - 14 Oct 2019
ImaginAb signs multi-party collaboration agreement with three global pharmaceutical companies to help further develop company's CD8 ImmunoPET technology
Biopharmaceuticals Oncology Radiology

HSMN NewsFeed - 30 Sep 2019
Arix Bioscience plc: Arix Co-leads EUR 20 Million Series A Investment Round in STipe Therapeutics
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 22 Aug 2019
Torque Expands Leadership Team with Appointment of Sok Cheng Soh as CFO and Ana Radeljevic as VP, Head of Business Operations
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 1 Aug 2019
Nektar Therapeutics and Bristol-Myers Squibb Announce U.S. FDA Breakthrough Therapy Designation for Bempegaldesleukin (NKTR-214) in Combination with Opdivo(R) (nivolumab) for the Treatment of Patients with Untreated Advanced Melanoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 27 Jun 2019
OncoSec Receives Exclusive Licensing Rights from Dana-Farber Cancer Institute to CAR T-Cell Therapies for the Treatment of Solid Tumor Cancers
Biopharmaceuticals Oncology Licensing

HSMN NewsFeed - 18 Jun 2019
FDA Grants Fast Track Designation for Torque's First Deep-Primed T Cell Cancer Immunotherapy Program, TRQ-1501
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 15 May 2019
IO Biotech Initiates Global Phase 2 Portion of Clinical Trial For T-win(R) Immunotherapy in Non-small Cell Lung Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 29 Mar 2019
Allogeneic CAR-T Specialists TC BioPharm Appoint Prof John Anderson as Scientific and Medical Director
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 26 Feb 2019
ImaginAb Announces change in management and strengthening of the Board of Directors and the Scientific Advisory Board
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 7 Feb 2019
Marker Therapeutics Appoints Mythili Koneru, M.D., Ph.D. as Senior Vice President, Clinical Development
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 22 Jan 2019
European Commission Approves BLINCYTO(R) (blinatumomab) In Patients With Philadelphia Chromosome Negative Minimal Residual Disease-Positive B-cell Precursor Acute Lymphoblastic Leukemia
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 8 Jan 2019
Cellenkos, Inc. Appoints Elizabeth Read as Chief Technology Officer, Adding Technology and Regulatory Affairs Expertise to its Executive Team
Biopharmaceuticals Personnel

HSMN NewsFeed - 12 Nov 2018
Arix Bioscience plc: Arix Participates in Harpoon $70m Series C Investment Round
Biopharmaceuticals Oncology Venture Capital

HSMN NewsFeed - 2 Nov 2018
Torque Announces Appointment of Immunotherapy Pioneer F. Stephen Hodi, MD, to Scientific Advisory Board and Alex Bruni as COO/ CFO
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 29 Aug 2018
European Commission Approves BLINCYTO(R) (blinatumomab) For Use In Pediatric Patients With Philadelphia Chromosome-Negative Relapsed Or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 8 Aug 2018
SQZ Biotech Completes Oversubscribed $72 Million Series C Financing
Biopharmaceuticals Venture Capital Personnel

HSMN NewsFeed - 8 Aug 2018
Janssen Submits U.S. & EU Regulatory Applications Seeking Approval of DARZALEX(R) (daratumumab) Split Dosing Regimen
Biopharmaceuticals Oncology FDA Regulatory

HSMN NewsFeed - 8 Aug 2018
Apexigen Raises $73 Million In Series B And Series C Financings
Biopharmaceuticals Oncology Venture Capital Personnel

HSMN NewsFeed - 25 Jul 2018
Torque Appoints James Mullen as Chairman of Board of Directors, Maykin Ho, PhD, as Strategic Advisor to the Board of Directors, and Mario Sznol, MD, to Scientific Advisory Board
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 23 Jul 2018
Sangamo Therapeutics to Acquire TxCell
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 2 Jul 2018
Phase III IMpassion130 Study Showed Genentech's TECENTRIQ Plus Abraxane Significantly Reduced the Risk of Disease Worsening or Death in People With Metastatic or Locally Advanced Triple Negative Breast Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 27 Jun 2018
Adicet Bio appoints Stewart Abbot, Ph.D. as Chief Scientific Officer
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 14 Jun 2018
Apexigen and Yale Cancer Center Announce Clinical Collaboration to Evaluate APX005M, Cabiralizumab, and Opdivo (Nivolumab) in Patients whose Disease has Progressed on Anti-PD-1/PD-L1 Therapy
Biopharmaceuticals Oncology

HSMN NewsFeed - 11 Jun 2018
IO Biotech Appoints Kathleen Sereda Glaub as Member of Board of Directors
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 30 May 2018
Legend Announces FDA Clearance of IND Application on CAR-T Immuno-cell Therapy for the Treatment of Multiple Myeloma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 17 May 2018
ImaginAb Reconstitutes Scientific Advisory Board
Biopharmaceuticals Oncology Radiology Personnel

HSMN NewsFeed - 16 May 2018
TapImmune Creates Scientific Advisory Board to Support Clinical Development of Multi-Antigen Cell Therapy Platform
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 30 Apr 2018
Adicet Bio appoints Elizabeth "EJ" Read, M.D. as Chief Technology Officer
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 13 Apr 2018
Cellenkos, Inc. Announces Alick Sun as Senior Vice President for Corporate and Business Development
Biopharmaceuticals Personnel

HSMN NewsFeed - 10 Apr 2018
TCR2 Therapeutics Appoints Leading Biotech Analyst Ian Somaiya as Chief Financial Officer
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 21 Mar 2018
TCR2 Therapeutics Raises $125 Million in Oversubscribed Series B Financing
Biopharmaceuticals Oncology Venture Capital

HSMN NewsFeed - 14 Mar 2018
Torque Appoints John Hohneker, MD, to Board of Directors and Marcela Maus, MD, PhD, to Scientific Advisory Board
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 8 Mar 2018
Infinity Pharmaceuticals Announces Additions to Board of Directors and Clinical Leadership Team and Establishes Scientific Advisory Board
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 5 Mar 2018
Aridis Pharmaceuticals, Inc. Appoints Wolfgang Dummer, M.D., Ph.D., as Chief Medical Officer, and Mitchell H. Rosner, Ph.D. as Vice President of Quality
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 5 Feb 2018
Tessa Therapeutics Announces Opening of Recruitment Sites Across the United States for its Phase III Nasopharyngeal Cancer Immunotherapy Trial
Biopharmaceuticals Oncology

HSMN NewsFeed - 17 Jan 2018
Novartis granted US FDA Priority Review for Kymriah(TM) (tisagenlecleucel), formerly CTL019, for adults with r/r DLBCL
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 3 Jan 2018
Agenus Announces Key Leadership to Advance Combination Trials For Planned BLA Filings
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 25 Dec 2017
I-Mab Biopharma Signs Licensing Agreement for HyLeukin With Genexine
Biopharmaceuticals Oncology Licensing

HSMN NewsFeed - 12 Dec 2017
DARZALEX(R) (daratumumab) Combination Regimen Significantly Improved Outcomes for Newly Diagnosed Multiple Myeloma Patients who are Transplant Ineligible
Biopharmaceuticals Oncology

HSMN NewsFeed - 7 Nov 2017
Pique Therapeutics Announces Positive Results in Phase 2 Clinical Trial of Lead Immunotherapy for Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 25 Sep 2017
TapImmune Appoints Peter Hoang as President and Chief Executive Officer
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 21 Sep 2017
European Commission Approves Bavencio (avelumab) for Metastatic Merkel Cell Carcinoma
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 29 Aug 2017
ARMO BioSciences Raises $67 Million in a Series C-1 Financing
Biopharmaceuticals Oncology Venture Capital Personnel

HSMN NewsFeed - 21 Jul 2017
EMA's CHMP Issues Positive Opinion for Avelumab for the Treatment of Metastatic Merkel Cell Carcinoma
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 19 Jul 2017
BD Receives FDA 510(k) Clearance for New Immunological Diagnostic System
Devices Diagnostics FDA

HSMN NewsFeed - 8 Jun 2017
QIAGEN's QuantiFERON(R)-TB Gold Plus gains U.S. FDA approval
Diagnostics FDA

HSMN NewsFeed - 5 Jun 2017
New Data Presented at ASCO 2017 Finds IMBRUVICA(R) (ibrutinib) May Offer a More Targeted Approach to Chronic Lymphocytic Leukemia (CLL) Treatment than Chemotherapy Agent Chlorambucil in Treatment-Naïve Patients
Biopharmaceuticals Oncology

HSMN NewsFeed - 16 May 2017
Dragonfly Therapeutics Announces Head of Biology
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 9 May 2017
FDA Grants BAVENCIO(R) (avelumab) Approval for a Common Type of Advanced Bladder Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 9 May 2017
Takeda and GammaDelta Therapeutics Announce Collaboration to Advance Tissue-derived gamma delta (γδ) T Cells
Biopharmaceuticals Oncology

HSMN NewsFeed - 8 May 2017
Regeneron and Inovio Enter Immuno-Oncology Clinical Study Agreement for Glioblastoma Combination Therapy
Biopharmaceuticals Oncology

HSMN NewsFeed - 3 May 2017
GammaDelta Therapeutics Expands Management Team Led by Paolo Paoletti as CEO
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 26 Apr 2017
Asterias Announces Publication of Positive Phase 2 Data on AST-VAC1 for the Treatment of Acute Myeloid Leukemia (AML) in 'Cancer'
Biopharmaceuticals Regenerative Medicine Oncology

HSMN NewsFeed - 24 Apr 2017
Mustang Bio Announces Appointment of Manuel Litchman, M.D., as President and Chief Executive Officer
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 19 Apr 2017
Advaxis Appoints Anthony Lombardo as Chief Business Officer
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 18 Apr 2017
Novartis CAR-T cell therapy CTL019 receives FDA Breakthrough Therapy designation for treatment of adult patients with r/r DLBCL
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 21 Mar 2017
George Bickerstaff Elected to Inovio’s Board of Directors
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 9 Mar 2017
OncoResponse Announces Final Closing of $22.5M Series A Financing Round
Biopharmaceuticals Oncology Personnel Venture Capital

HSMN NewsFeed - 8 Mar 2017
Celyad obtains FDA approval to initiate the NKR-2 CAR T cells THINK trial in the USA
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 2 Mar 2017
BLINCYTO(R) (blinatumomab) Significantly Improved Overall Survival In Patients With B-Cell Precursor Acute Lymphoblastic Leukemia Compared To Chemotherapy
Biopharmaceuticals Oncology

HSMN NewsFeed - 27 Jan 2017
Juno Therapeutics Appoints Corsee D. Sanders as Executive Vice President and Head of Development Operations
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 26 Jan 2017
Celgene to Acquire Delinia, Inc.
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 20 Jan 2017
Verastem Announces Executive Leadership Appointments and Changes
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 22 Nov 2016
DARZALEX(R) (daratumumab) Approved by U.S. FDA in Combination with Two Standard of Care Regimens for the Treatment of Patients with Multiple Myeloma Who Have Received At Least One Prior Therapy
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 14 Nov 2016
Inovio’s Cancer Immunotherapy (INO-3112) Generates T Cell Immune Responses in Tumor Tissue and Peripheral Blood in Patients with HPV-Associated Head and Neck Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 2 Nov 2016
Verastem Licenses Duvelisib from Infinity Pharmaceuticals
Biopharmaceuticals Oncology Licensing

HSMN NewsFeed - 12 Oct 2016
Inovio Expands Executive Team to Advance its DNA Immunotherapy Product Portfolio
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 4 Aug 2016
Inovio Pharmaceuticals Appoints Dr. Ami Shah Brown As Vice President Regulatory Affairs
Biopharmaceuticals Personnel

HSMN NewsFeed - 28 Jul 2016
Caladrius Biosciences Receives FDA Fast Track Designation for CLBS03 to Treat Recent Onset Type 1 Diabetes
Biopharmaceuticals Endocrinology FDA

HSMN NewsFeed - 12 Jul 2016
Advaxis Appoints Ranya Dajani as Vice President, Corporate Development
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 20 May 2016
Avalon Ventures and COI Pharmaceuticals Announce First Milestones for Sitari Pharmaceuticals and Silarus Therapeutics and Formation of Eighth Company
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 17 May 2016
Nouscom Concludes Successful Series A Financing of EUR 12 Million
Biopharmaceuticals Oncology Venture Capital

HSMN NewsFeed - 11 Apr 2016
FDA Grants Priority Review for Genentech’s Cancer Immunotherapy Atezolizumab in Specific Type of Lung Cancer
Biopharmaceuticals Personalized Medicine Oncology FDA

HSMN NewsFeed - 15 Feb 2016
Collaboration led by ImmunID Awarded Innovate UK Grant to Advance Program on Prediction of Response to Cancer Immunotherapy using ImmunTraCkeR(R)
Diagnostics Personalized Medicine Oncology

HSMN NewsFeed - 4 Feb 2016
Phase 3 Study of BLINCYTO(R) (Blinatumomab) Met Primary Endpoint Of Overall Survival In Patients With B-Cell Precursor Acute Lymphoblastic Leukemia
Biopharmaceuticals Oncology

HSMN NewsFeed - 6 Jan 2016
Vernalis Announces Corvus Pharmaceuticals, Inc. as Its Worldwide Licensee for Their Adenosine Antagonist Program
Biopharmaceuticals Licensing

HSMN NewsFeed - 24 Nov 2015
European Commission Approves Amgen's BLINCYTO(R) (blinatumomab) for the Treatment of Adults with Philadelphia Chromosome-Negative Relapsed or Refractory B-precursor Acute Lymphoblastic Leukemia
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 29 Sep 2015
Corvus Pharmaceuticals Completes $75 Million Series B Financing
Biopharmaceuticals Oncology Venture Capital

HSMN NewsFeed - 10 Aug 2015
Inovio Pharmaceuticals Enters Into Strategic Cancer Vaccine Collaboration and License Agreement With MedImmune
Biopharmaceuticals Licensing

HSMN NewsFeed - 3 Aug 2015
CytomX Announces Management Team Promotions
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 13 Jul 2015
In a Pivotal Study, Genentech’s Investigational Immunotherapy Atezolizumab Shrank Tumors in People With a Specific Type of Bladder Cancer
Biopharmaceuticals Oncology Urology

HSMN NewsFeed - 17 Dec 2014
Inovio Pharmaceuticals Appoints Zane Yang, M.D. Vice President, Clinical Development, Oncology
Biopharmaceuticlas Oncology Personnel

HSMN NewsFeed - 27 Aug 2014
Bellicum Pharmaceuticals Secures $55 Million in Oversubscribed Series C Financing
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 14 Apr 2014
Kite Pharma Expands Leadership Team and Announces Senior Management Promotions
Biopharmaceuticals Personnel

HSMN NewsFeed - 18 Mar 2014
Immune Design Appoints Franklin M. Berger to Board of Directors
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 6 Mar 2014
Immune Design Appoints William Ringo to Board of Directors
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 17 Feb 2014
CoStim Pharmaceuticals, Inc. Acquired by Novartis
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 7 Jan 2014
Bellicum Pharmaceuticals Raises $34.4 Million in a Series B Financing
Biopharmaceuticals Oncology Venture Capital

HSMN NewsFeed - 30 Oct 2013
Immune Design Raises Up to $49 Million Series C Financing
Biopharmaceuticals Venture Capital Personnel

HSMN NewsFeed - 10 Oct 2012
Genocea Closes $30 Million in Series C Financing
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 18 Sep 2012
Circassia Appoints Stewart Sharpe as Vice President Commercial Operations
Biopharmaceuticals Personnel

HSMN NewsFeed - 26 Jan 2012
Amgen to Acquire Micromet
Biopharmaceuticals Oncology Mergers & Acquisitions

HSMN NewsFeed - 20 Jan 2012
Galena Biopharma Initiates Patient Enrollment in NeuVax(TM) Phase 3 PRESENT Trial to Prevent Breast Cancer Recurrence
Biopharmaceuticals Oncology

HSMN NewsFeed - 4 Jan 2012
NexImmune Appoints Kenneth Carter, PhD, as President and CEO and Jonathan Schneck, MD, PhD as Chairman of Clinical and Scientific Advisory Board
Biopharmaceuticals Personnel

HSMN NewsFeed - 11 Oct 2011
Aduro BioTech Announces First Patient Treated in Phase 2 Pancreatic Cancer Trial
Biopharmaceuticals Oncology

HSMN NewsFeed - 4 Oct 2011
Galena Biopharma Hires Hana B. Moran as Vice President, Regulatory Affairs and Compliance
Biopharmaceuticals Personnel

HSMN NewsFeed - 6 Sep 2011
Inovio Pharmaceuticals Adds Two Medical Innovators to Its Scientific Advisory Board
Biopharmaceuticals Personnel

HSMN NewsFeed - 31 Mar 2011
RXi Pharmaceuticals Aggressively Moves into Late-Stage Clinical Development with the Agreement to Acquire Apthera, Inc.
Biopharmaceuticals Oncology Mergers & Acquisitions

HSMN NewsFeed - 12 Aug 2010
Genocea Biosciences Hires Chip Clark as Chief Business Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 7 Jun 2010
Cytheris Closes 12 Million ($15 Million) Series D Financing
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 22 Apr 2010
Novartis Receives US FDA Approval for Zortress(R) (everolimus) to Prevent Organ Rejection in Adult Kidney Transplant Recipients
Biopharmaceuticals FDA

HSMN NewsFeed - 23 Mar 2010
Oncothyreon announces temporary suspension of Stimuvax clinical trials by Merck Serono
Biopharmaceuticals Oncology

HSMN NewsFeed - 7 Dec 2009
Adamis Pharmaceuticals Announces Signing of Definitive Merger Agreement
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 7 Dec 2009
La Jolla Pharmaceutical Company Announces Signing of Definitive Merger Agreement With Adamis Pharmaceuticals
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 2 Dec 2009
ImmunoCellular Therapeutics Enters into Option Agreement with The University of Texas M. D. Anderson Cancer Center for a Novel Cancer Stem Cell Therapy
Regenerative Medicine Oncology

HSMN NewsFeed - 2 Sep 2009
FDA Advisory Committee Recommends Gloucester Pharmaceuticals' Romidepsin for Approval for Cutaneous T-cell Lymphoma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 4 Aug 2009
DOR BioPharma Receives FDA Orphan Drug Designation for orBec(R) for the Treatment of Chronic Gastrointestinal GVHD
Biopharmaceuticals FDA

HSMN NewsFeed - 10 Mar 2009
Tolerx Expands Phase 3 'DEFEND' Trial of Otelixizumab in Europe
Biopharmaceuticals Endocrinology

HSMN NewsFeed - 23 Feb 2009
Micromet Adds Former Head of Roche Oncology Kapil Dhingra, MD to Board of Directors
Biopharmaceuticals Personnel

HSMN NewsFeed - 23 Jan 2009
Geron Receives FDA Clearance to Begin World's First Human Clinical Trial of Embryonic Stem Cell-Based Therapy
Regenerative Medicine Neurosurgery FDA

HSMN NewsFeed - 19 Sep 2008
Maxygen and Astellas Announce Global Agreement to Develop New Therapies for Autoimmune Diseases and Transplantation
Biopharmaceuticals

HSMN NewsFeed - 29 Jul 2008
Advaxis Incorporated Receives List of Questions from the U.S. Food and Drug Administration
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 21 Apr 2008
Graceway Pharmaceuticals Reports Study in New England Journal of Medicine: ALDARA(R) (imiquimod) Cream, 5% demonstrated a reduction in lesion size in patients with vulvar intraepithelial neoplasia (VIN)
Biopharmaceuticals

HSMN NewsFeed - 15 Apr 2008
Kiadis Pharma Receives Orphan Drug Designation for Rhitol(TM) From the FDA
Biopharmaceuticals FDA

HSMN NewsFeed - 25 Mar 2008
Ceragenix Enters into Agreement to License CSA-54 and other Ceragenin Compounds To Biopharmaceutical Company for HIV and STD Applications
Biopharmaceuticals HIV/AIDS Licensing

HSMN NewsFeed - 25 Mar 2008
Micromet Establishes New Scientific Advisory Board for Its BiTE Antibody Technology with Leading Experts in the Fields of Oncology, Immunotherapy and Drug Development
Biopharmaceuticals Personnel

HSMN NewsFeed - 5 Mar 2008
Kyowa Hakko and Amgen Enter Licensing Agreement for Anti-CCR4 Humanized Monoclonal Antibody
Biopharmaceuticals Licensing

HSMN NewsFeed - 4 Feb 2008
Traversa Raises $2M to Advance RNAi Delivery in Angel-Led Series A Financing
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 17 Dec 2007
Lilly and BioMS Medical Announce Global Licensing and Development Agreement
Biopharmaceuticals Neurology Licensing

HSMN NewsFeed - 14 Dec 2007
Micromet Announces Changes in Management Team
Biopharmaceuticals Personnel

HSMN NewsFeed - 26 Nov 2007
Cytheris Appoints Richard Keatinge as Chief Business Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 16 Nov 2007
Argos Therapeutics and Therakos, Inc. Enter Exclusive Agreement for Regulatory T Cell Technology
Biopharmaceuticals Licensing

HSMN NewsFeed - 23 Oct 2007
GlaxoSmithKline and Tolerx Form Worldwide Collaboration for Development and Commercialization of Novel Medication
Biopharmaceuticals

HSMN NewsFeed - 18 Oct 2007
Lilly and MacroGenics Announce Licensing and Collaboration Agreement
Biopharmaceuticals Licensing

HSMN NewsFeed - 12 Sep 2007
Micromet Appoints Mark Reisenauer as Senior Vice President and Chief Commercial Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 19 Jul 2007
Micromet Promotes Carsten Reinhardt to Chief Medical Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 9 Jul 2007
World's First Therapeutic Vaccine for Brain Cancer Commercially Available to Patients in Switzerland
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 4 Jun 2007
Final Data from a Phase 2 Trial Presented at ASCO Specifies Dose-dependent Activity of Adecatumumab (MT201)
Biopharmaceuticals Oncology

HSMN NewsFeed - 9 May 2007
Dendreon Receives Complete Response Letter From FDA for Provenge(R) Biologics License Application
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 26 Apr 2007
PDL BioPharma Advances Nuvion(R) Into Second Pivotal Study in Intravenous Steroid-Refractory Ulcerative Colitis
Biopharmaceuticals Gastroenterology

HSMN NewsFeed - 20 Mar 2007
DOR BioPharma Forms orBec(R) Medical Advisory Board
Biopharmaceuticals Personnel

HSMN NewsFeed - 16 Mar 2007
Micromet and TRACON Pharmaceuticals Sign Exclusive Worldwide License Agreement to Develop and Commercialize D93, a Humanized Antibody for Cancer Treatment
Biopharmaceuticals Licensing

HSMN NewsFeed - 12 Mar 2007
Primary Endpoint Met in Phase 2 Trial of Daclizumab in Patients With Relapsing Multiple Sclerosis
Biopharmaceuticals Neurology

HSMN NewsFeed - 12 Feb 2007
Morphotek Obtains Exclusive License from Micromet for Antibody to Treat Melanoma and Other Cancers
Biopharmaceuticals Licensing

HSMN NewsFeed - 4 Jan 2007
Medarex Announces Enrollment Complete in Ipilimumab (MDX-010) Monotherapy Pivotal Registrational Trial for Metastatic Melanoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 28 Dec 2006
SciClone and Sigma-Tau Complete Enrollment in Phase 3 Triple Therapy Hepatitis C Clinical Trial
Biopharmaceuticals

HSMN NewsFeed - 12 Dec 2006
INNOVIVE Pharmaceuticals Presents Data on Oncology Drug Programs in Chronic Myelogenous Leukemia and Acute Myelogenous Leukemia at American Society of Hematology 48th Annual Meeting
Biopharmaceuticals Oncology

HSMN NewsFeed - 7 Dec 2006
Medarex Announces FDA Fast Track Designations for Ipilimumab for the Treatment of Metastatic Melanoma; Fast Track Designations for First-Line Use in Combination With Chemotherapy and Second-Line Use as Monotherapy
Biopharmaceuticals FDA Oncology

HSMN NewsFeed - 5 Dec 2006
Micromet, Inc. and Serono Amend Collaboration Agreement and Continue Development of Adecatumumab (MT201)
Biopharmaceuticals Oncology

HSMN NewsFeed - 13 Nov 2006
Favrille Announces Interim Analysis of Secondary Endpoint from Pivotal Phase 3 Clinical Trial of FavId Following Rituxan in Follicular B-Cell Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 9 Nov 2006
Two-Year Data for ORENCIA(R) (abatacept) Demonstrate Continued Efficacy in Adults With Rheumatoid Arthritis
Biopharmaceuticals

HSMN NewsFeed - 12 Oct 2006
Micromet, Inc. Expands Management and Appoints Christopher P. Schnittker as Senior Vice President and Chief Financial Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 10 Oct 2006
MacroGenics Receives Orphan Drug Designation From FDA for Monoclonal Antibody to Treat Type 1 Diabetes
Biopharmaceuticals Endocrinology FDA

HSMN NewsFeed - 2 Oct 2006
Updated REVLIMID(R) (lenalidomide) Clinical Results Presented at the 3rd International Conference on Innovative Therapies for Lymphoid Malignancies
Biopharmaceuticals Oncology

HSMN NewsFeed - 2 Oct 2006
Final Data From Two Phase II Trials Indicate Activity of Adecatumumab (MT201) in Breast and Prostate Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 5 May 2006
Micromet and CancerVax Complete Merger To Form Micromet, Inc.
Biopharmaceuticals Mergers & Acquisitions

Return to NewsFeed

Additional items found! 88

Members: click here for search results from The HSMN Archive (password required)

Members Archive contains 88 additional stories matching:
T cells
(Password required)

FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.

RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!